Cargando…

Rethinking the role of COVID-19 convalescent plasma in the critically ill

Detalles Bibliográficos
Autores principales:	Casadevall, Arturo, Pirofski, Liise-anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351135/ https://www.ncbi.nlm.nih.gov/pubmed/35941021 http://dx.doi.org/10.1016/j.transci.2022.103521

Ejemplares similares

Rethinking T cell immunity in oropharyngeal candidiasis
por: Pirofski, Liise-anne, et al.
Publicado: (2009)

COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic
por: Pirofski, Liise-anne
Publicado: (2023)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Exploiting the Redundancy in the Immune System: Vaccines Can Mediate Protection by Eliciting ‘Unnatural’ Immunity
por: Casadevall, Arturo, et al.
Publicado: (2003)

Immune-Mediated Damage Completes the Parabola: Cryptococcus neoformans Pathogenesis Can Reflect the Outcome of a Weak or Strong Immune Response
por: Pirofski, Liise-anne, et al.
Publicado: (2017)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework
por: Pirofski, Liise-anne, et al.
Publicado: (2020)

Understanding vaccine hesitancy in COVID-19
por: Trogen, Brit, et al.
Publicado: (2021)

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Q and A What is a pathogen? A question that begs the point
por: Pirofski, Liise-anne, et al.
Publicado: (2012)

The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases
por: Casadevall, Arturo, et al.
Publicado: (2015)

What is infectiveness and how is it involved in infection and immunity?
por: Pirofski, Liise-anne, et al.
Publicado: (2015)

The Damage–Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases
por: Pirofski, Liise-anne, et al.
Publicado: (2018)

Benefits and Costs of Animal Virulence for Microbes
por: Casadevall, Arturo, et al.
Publicado: (2019)

Immunomodulators as an antimicrobial tool
por: Pirofski, Liise-anne, et al.
Publicado: (2006)

The damage-response framework of microbial pathogenesis
por: Casadevall, Arturo, et al.
Publicado: (2003)

The weapon potential of a microbe
por: Casadevall, Arturo, et al.
Publicado: (2004)

The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases
por: Pirofski, Liise-anne, et al.
Publicado: (2008)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

Functional Antibodies in COVID-19 Convalescent Plasma
por: Herman, Jonathan D., et al.
Publicado: (2021)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
por: Klassen, Stephen A., et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Serosurveys and convalescent plasma in COVID-19
por: Pérez-Cameo, Cristina, et al.
Publicado: (2020)

COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON
por: Casadevall, Arturo, et al.
Publicado: (2022)

Microbial Virulence as an Emergent Property: Consequences and Opportunities
por: Casadevall, Arturo, et al.
Publicado: (2011)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
por: Tirnea, Livius, et al.
Publicado: (2021)

Towards characterized convalescent plasma for COVID-19: The dose matters
por: Verkerke, Hans P., et al.
Publicado: (2020)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes
por: Alvarez, Mauricio, et al.
Publicado: (2009)

Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19
por: Nnaji, Chukwudi Arnest, et al.
Publicado: (2020)

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
por: Klassen, Stephen A., et al.
Publicado: (2021)

Clinical outcomes of using plasma in COVID-19 convalescent critically ill patients
por: Astola Hidalgo, I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h40g8d46do9v2jr0v458fu8dqm